Format

Send to

Choose Destination
Clin Transl Oncol. 2015 Feb;17(2):103-12. doi: 10.1007/s12094-014-1248-9. Epub 2014 Oct 29.

Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Author information

1
Department of Medical Oncology, Oncology Service, Hospital Universitari Vall d'Hebron, P. Vall d'Hebron, 119-129, 08035, Barcelona, Spain, efelip@vhebron.net.

Abstract

In 2011, the Spanish Society of Medical Oncology and the Spanish Society of Pathology started a joint project to establish recommendations on biomarker testing in patients with advanced non-small-cell lung cancer based on the current evidence. Most of these recommendations are still valid, but new evidence requires some aspects to be updated. Specifically, the recommendation about which biomarkers to test in which patients is being amended, and the best way to manage tumour samples and minimum requirements for biomarker test material are defined. Suitable techniques for testing for epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement are also reviewed, and a consensus is reached on which situations warrant re-biopsy.

PMID:
25351175
DOI:
10.1007/s12094-014-1248-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center